MPC Therapeutics Announces the Commercial Launch of MitoStem™
MPC Therapeutics launched MitoStem™, an ex vivo metabolic enhancer designed to improve CAR-T and engineered cell therapy performance by increasing durable, stem-like T-cell populations.
Source: Plutus / MPC Therapeutics